Journal
CANCER LETTERS
Volume 403, Issue -, Pages 224-230Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2017.06.024
Keywords
Glioblastoma; EGFRvIII; Vaccine; CAR T-cell therapy
Categories
Ask authors/readers for more resources
Glioblastoma multiforme (GBM) is the most progressive primary brain tumor. Targeting a novel and highly specific tumor antigen is one of the strategies to overcome tumors. EGFR variant III (EGFRvIII) is present in 25%-33% of all patients with GBM and is exclusively expressed on tumor tissue cells. Currently, there are various approaches to target EGFRvIII, including CAR T-cell therapy, therapeutic vaccines, antibodies, and Bi-specific T Cell Engager. In this review, we focus on the preclinical and clinical findings of targeting EGFRvIII for GBM. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available